- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01828255
Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients
September 15, 2020 updated by: Sensimed AG
A Single Center, Case-control, Open Label Study Assessing Intraocular Pressure Patterns in Patients With Primary Open-angle Glaucoma Experiencing Fast Versus Slow Visual Field Progression
The purpose of this study is to investigate how the intraocular pressure (IOP) varies in time and if the IOP variations are associated with the worsening of glaucoma.
IOP patterns will be recorded continuously over 24 hours with SENSIMED Triggerfish® (TF) a portable investigational device using a contact lens sensor.
After completing the Triggerfish lens placement and removal; the patient will complete a formal Polysomnography.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- The New York Eye and Ear Infirmary
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 89 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 40 and 89 years old
- Diagnosis of treated POAG (including normal tension glaucoma (NTG))
- All IOP measurements during the VF period (to be described further) equal or lower than 18 mmHg and/or on average equal or lower than 16 mmHg in the same period
- Documented glaucomatous VF damage at baseline, characterized by glaucoma hemifield test result outside normal limits on at least 2 consecutive VF tests or the presence of at least 3 contiguous test points within the same hemifield on the pattern deviation plot at p<0.01, with at least 1 point at p < 0.005
- At least 8 visual field tests carried out within at least 2 years, all with fixation losses and false positive/negative results equal or less than 33%
- For fast progressing eyes, 1) pointwise progression defined as two or more adjacent VF test locations in the same hemifield that show a threshold sensitivity rate of change more negative than -1.0 dB/year with p<0.01 or 2) a global rate of VF change based on mean deviation (MD) more negative than -1.0 dB/year
- For slowly or minimally progressing eyes a VF MD rate of change more positive than -0.5 dB/year with no significant pointwise progression as described above
- Not more than 6 diopters spherical equivalent on the study eye
- Have given written informed consent, prior to any investigational procedures
Exclusion Criteria:
- Baseline VF MD more negative than -15 dB. The rationale here is that in severely damaged visual fields, one may not be able to detect and measure rates of progression due to a 'floor effect'
- Corneal or conjunctival abnormality precluding contact lens adaptation
- Severe dry eye syndrome or other ocular disease
- Patients with angle closure glaucoma, traumatic glaucoma or uveitic glaucoma
- Patients with previous intraocular surgery in the enrolled eye, including cataract surgery
- Patients with allergy to corneal anesthetic
- Patients with contraindications for silicone contact lens wear
- Patients not able to understand the character and individual consequences of the investigation
- Participation in unrelated clinical research within the last 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SENSIMED Triggerfish®
Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder.
Upon completion, the recording can be transmitted to a computer for read-out and visualization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship Between 24-hour IOP Pattern as Recorded by TF and VF Progression in Patients With POAG.
Time Frame: 24-hour
|
24-hour measurement of TF, corresponding to IOP-related fluctuations expressed in arbitrary units of mini volts equivalent (mVeq) and comparison of this measurement between POAG patients showing fast and slow rates of glaucoma visual field progression.
|
24-hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship Between TF Pattern and VF Progression According to TF Slope
Time Frame: 24-hour
|
Measurement of TF, corresponding to IOP-related fluctuations expressed in arbitrary units of mini volts equivalent (mVeq) and comparison of this measurement between POAG patients showing fast and slow rates of glaucoma visual field progression during wake vs sleep periods.
The wake slope corresponds to the change in the TF signal from 1 hour before to 1 hour after the time the subject went to sleep.
The sleep slope corresponds to the change from 1 hour before to 1 hour after the time the subject awoke.
|
24-hour
|
Relationship Between TF Pattern and VF Progression According to Day and Night
Time Frame: 24-hour
|
TF measurement during diurnal and nocturnal periods and comparison of this measurement between POAG patients showing fast and slow rates of glaucoma visual field progression.
|
24-hour
|
Relationship Between 24-hour TF Pattern and VF Progression According to TF Peak
Time Frame: 24-hour
|
Number of peaks in 24-Hours TF pattern, defined as the local maximum point in the smoothed TF profile.
|
24-hour
|
24-hour TF IOP Pattern in Patients With POAG With Fast and Slow Rates of VF Progression
Time Frame: 24-hour
|
Comparison (Spearman correlations) between 24-hour IOP-related fluctuations measured by TF and 24-hour blood pressure profiles (systolic, diastolic and mean arterial blood pressure) of POAG patients showing fast and slow rates of glaucoma visual field progression.
The correlation between TF and blood pressure measurement was calculated within each subject then mean values were obtained for patients with slow vs fast glaucoma visual field progression.
|
24-hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gustavo De Moraes, MD, The New York Eye and Ear Infirmary
- Principal Investigator: Jeffrey M Liebmann, MD, The New York Eye and Ear Infirmary
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
April 5, 2013
First Submitted That Met QC Criteria
April 5, 2013
First Posted (Estimate)
April 10, 2013
Study Record Updates
Last Update Posted (Actual)
October 9, 2020
Last Update Submitted That Met QC Criteria
September 15, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TF-1212
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open-angle Glaucoma (POAG) Patient
-
Implandata Ophthalmic Products GmbHCompletedPrimary Open Angle Glaucoma (POAG)Germany
-
University Hospital, GrenobleNot yet recruitingPrimary Open-angle Glaucoma (POAG)
-
Alcon ResearchTranscend Medical, Inc.CompletedPrimary Open Angle Glaucoma (POAG)United States
-
Transcend Medical, Inc.CompletedPrimary Open Angle Glaucoma (POAG)
-
Glaukos CorporationCompletedPrimary Open Angle Glaucoma (POAG)Armenia
-
Glaukos CorporationTerminatedPrimary Open Angle Glaucoma (POAG)Brazil
-
Glaukos CorporationCompletedOne, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsPrimary Open Angle Glaucoma (POAG)Armenia
-
Glaukos CorporationCompletedSubjects With Primary Open-angle Glaucoma (POAG)Armenia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOcular Hypertension | Glaucoma, Primary Open Angle (POAG)France
-
Qlaris Bio, Inc.RecruitingPrimary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)United States
Clinical Trials on SENSIMED Triggerfish®
-
Sensimed AGCompletedSleep Apnea, Obstructive | Primary Open-angle GlaucomaUnited States
-
Sensimed AGClinique MonchoisiTerminatedPrimary Open Angle GlaucomaSwitzerland
-
Sensimed AGCompleted
-
University Hospital, BordeauxCompletedOpen Angle Glaucoma With a Progressive Visual FieldFrance
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Normal Tension GlaucomaPoland
-
Sensimed AGWithdrawn
-
Sensimed AGTerminatedHealthy SubjectsSwitzerland
-
Sensimed AGUniversity Hospital, GenevaTerminated